In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
What else is new.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.